Infliximab Induction Strategies in Corticosteroid-Refractory Acute Severe Ulcerative Colitis: A Case Series and Literature Review

• Published in: GE Portuguese journal of gastroenterology Vol. 30; no. 5; pp. 390 - 397
• Main Authors: Antunes, Pedro Bernardes, Gonçalves, Bruno, Arroja, Bruno, Gonçalves, Raquel, Leal, Tiago
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01-10-2023; Karger Publishers
• Subjects: Abdomen; accelerated infliximab induction; acute severe ulcerative colitis; Anemia; Case reports; Clinical Case Study; Colon; Colonoscopy; Drug dosages; Emergency medical care; Endoscopy; Heart rate; Hemoglobin; Hospitalization; Inflammatory bowel disease; intensified infliximab induction; Monoclonal antibodies; Parenteral nutrition; Patients; Remission (Medicine); Response rates; Steroids; Toxicity; Tumor necrosis factor-TNF; Intensified infliximab induction; Acute severe ulcerative colitis; Accelerated infliximab induction
• ISSN: 2341-4545; 2387-1954
• DOI: 10.1159/000526509

Abstract
Acute severe ulcerative colitis (ASUC) is an emergent medical condition and particularly challenging to treat efficaciously. Infliximab is one of the medical salvage treatment options after corticosteroid refractoriness, but the best induction strategy is not yet defined. With this case series, the authors intend to describe three corticosteroid-refractory ASUC cases with different intensified/accelerated infliximab induction approaches and review the literature on this topic.The first case describes an 18-year-old girl with ASUC at disease onset with rapid progression to toxic megacolon, complicated also with anemia, hypoalbuminemia, and coagulopathy. After corticosteroid failure, both accelerated and intensified (10 mg/kg) infliximab regimen was completed within 11 days, with solid clinical response and colon imaging normalization. Second, we present a 26-year-old male with left-sided ulcerative colitis known for 2 years, under mesalazine, who developed a moderate flare and was started on infliximab after partial and inconsistent response to corticosteroids. During the induction period, he presented this time an ASUC episode, which motivated an early and intensified third dose with good clinical response. Finally, we describe the case of a 78-year-old man with ulcerative proctitis for 12 years presenting ASUC with proximal disease extension as well. After unsatisfactory response to corticosteroids, infliximab was initiated on an accelerated induction regimen, completed in 13 days, with the standard dose, achieving clinical remission. Accelerated or intensified infliximab induction plans are becoming current clinical practice in corticosteroid-refractory ASUC. Current guidelines refer to the possibility of this type of strategies, not determining the optimal regimen due to lack of solid evidence. Literature is mainly based on retrospective studies, not randomized, with heterogeneous groups according to disease severity, and the effect on colectomy rates, mainly on the long term, is not clear. Additional well-supported studies are needed on this subject in order to seek a more widely uniform approach.